Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH)

0.4013
Delayed Data
As of Apr 24
 -0.0127 / -3.07%
Today’s Change
0.36
Today|||52-Week Range
4.37
-38.18%
Year-to-Date
Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2%
Apr 12 / Zacks.com - Paid Partner Content
Should You Get Rid of Aimmune Therapeutics (AIMT) Now?
Apr 11 / Zacks.com - Paid Partner Content
ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
Apr 11 / Zacks.com - Paid Partner Content
BioTelemetry (BEAT) Shows Strength: Stock Moves 8.8% Higher
Apr 11 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close0.41
Today’s open0.42
Day’s range0.39 - 0.42
Volume1,281,414
Average volume (3 months)2,361,491
Market cap$32.2M
Dividend yield--
Data as of 04/24/2017

Growth & Valuation

Earnings growth (last year)-62.63%
Earnings growth (this year)--
Earnings growth (next 5 years)+78.00%
Revenue growth (last year)-95.45%
P/E ratioNM
Price/Sales184.93
Price/Book4.78

Competitors

 Today’s
change
Today’s
% change
PRPHProPhase Labs Inc-0.07-3.59%
AMPEAmpio Pharmaceutical...-0.01-1.49%
ADHDAlcobra Ltd+0.08+7.27%
NVLSNivalis Therapeutics...-0.16-7.08%
Data as of 04/24/2017

Financials

Next reporting dateMay 16, 2017
EPS forecast (this quarter)-$0.20
Annual revenue (last year)$145.0K
Annual profit (last year)-$55.5M
Net profit margin-38,291.72%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
John Craig Thompson
CAO, Senior VP-Finance &
Administration
May Liu
Corporate headquarters
Hayward, California

Forecasts


Search for Jobs